News
IMMX
2.350
+1.73%
0.040
Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma
European Orphan Drug Designation qualifies NXC-201 for 10 years of market exclusivity once authorized in the EU. The drug has reduced annual fees and access to the EU's centralized authorization procedure. The drug is approved for the European Orphan drug Designation.
Benzinga · 5d ago
Weekly Report: what happened at IMMX last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at IMMX last week (0415-0419)?
Weekly Report · 04/22 12:23
Immix Biopharma On Track To Dose NXC-201 U.S. Patients
Benzinga · 04/18 13:46
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Immix Biopharma, Inc. Is on track to dose NXC-201 patients in the U.S. With no change in patient enrollment timing. The company is developing cell therapies in AL Amyloidosis and other autoimmune diseases. Immix is a clinical-stage biopharmaceutical company.
Barchart · 04/18 08:32
Immix Biopharma Announces NXC-201 Clinical Data Abstract Accepted For Oral Presentation At 27th Annual Meeting Of ASGCT
Benzinga · 04/15 13:38
IMMIX BIOPHARMA ANNOUNCES LATE-BREAKING NXC-201 CLINICAL DATA ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT)
Reuters · 04/15 13:36
Weekly Report: what happened at IMMX last week (0408-0412)?
Weekly Report · 04/15 12:12
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Immix Biopharma's NXC-201 clinical data has been selected for presentation at the upcoming 27th Annual Meeting of The American Society of Gene & Cell Therapy in Baltimore May 7-11, 2024. The company is developing cell therapies in AL Amyloidosis and other autoimmune diseases.
Barchart · 04/15 08:36
Weekly Report: what happened at IMMX last week (0401-0405)?
Weekly Report · 04/08 12:19
Immix Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Immix Biopharma Inc reported a quarterly adjusted loss of 23 cents per share for the quarter ended in December. The company's reported revenue was zero; analysts expected zero. The average analyst rating on the company's shares is "buy" shares have fallen 57.8% so far this year.
Reuters · 04/02 15:55
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
Immix Biopharma reported earnings per share of -24 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -23 cents. Immix biopharma just reported results.
Investorplace · 04/02 11:53
Weekly Report: what happened at IMMX last week (0325-0329)?
Weekly Report · 04/01 12:15
Weekly Report: what happened at IMMX last week (0318-0322)?
Weekly Report · 03/25 12:18
Weekly Report: what happened at IMMX last week (0311-0315)?
Weekly Report · 03/18 12:17
Weekly Report: what happened at IMMX last week (0304-0308)?
Weekly Report · 03/11 12:11
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Immix Biopharma, Inc. Announces its new AL Amyloidosis awareness campaign Be Proactive in AL™. The campaign seeks to increase awareness about the critical need to recognize and diagnose AL Amylloidosis early and educate patients about treatment options. Immix is a clinical-stage biopharmaceutical company.
Barchart · 03/05 08:35
Weekly Report: what happened at IMMX last week (0226-0301)?
Weekly Report · 03/04 12:15
Weekly Report: what happened at IMMX last week (0219-0223)?
Weekly Report · 02/26 12:36
Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Immix Biopharma, Inc. Announced its 12-month progress update. NXC-201 is the only CAR-T in AL Amyloidosis and is expanding into additional autoimmune indications. The company received U.S. FDA Orphan Drug Designation for the treatment of multiple myeloma.
Benzinga · 02/21 14:39
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).